Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study

Autor: Neumair, P., Joos, L., Warschkow, R., Dutly, A., Ess, S., Hitz, F., Früh, M., Brutsche, M., Baty, F., Krähenbühl, S., Cerny, T., Joerger, M.
Zdroj: In Lung Cancer October 2016 100:38-44
Databáze: ScienceDirect